Skip to main content
Rosetta Genomics eyes sale of PersonalizeDx business

Rosetta Genomics has announced plans for a potential sale of its PersonalizeDx business, which markets fluorescence in situ hybridization-based cancer tests as part of its corporate strategy realignment to concentrate on the RosettaGx Reveal microRNA-based thyroid nodule classification assay. The sale "would have the benefit of bringing in nondilutive cash, as well as reducing our cash burn rate by approximately 20 percent," said company President and CEO Kenneth Berlin.

Full Story: